Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

주식 순위 #2117
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
주가
$164.43
마지막 동기화: 2026-10-16
시가총액
$9.70B
변동 (1일)
-0.95%
변동 (1년)
88.63%
국가
US
거래 Glaukos Corporation (GKOS)

카테고리

Healthcare
Glaukos Corporation (GKOS)의 EPS
June 2026 기준 EPS TTM: $-3.25
Glaukos Corporation의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-3.25입니다. 2023년 말에는 회사의 EPS가 $-2.78였으며, 이는 2022년의 EPS $-2.09와 증가입니다.
Glaukos Corporation의 EPS 기록 (2012 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-3.25 17.33%
2024 $-2.77 -0.36%
2023 $-2.78 33.01%
2022 $-2.09 95.33%
2021 $-1.07 -60.37%
2020 $-2.70 -758.54%
2019 $0.41 -210.81%
2018 $-0.37 13,603.70%
2017 0.00 -101.93%
2016 $0.14 -106.57%
2015 $-2.13 334.69%
2014 $-0.49 -3.92%
2013 $-0.51 -94.76%
2012 $-9.73 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$3.11 -195.69%
US
$3.59 -210.46%
IE
$9.73 -399.38%
US
$2.48 -176.31%
US
- -
DE